March 18, 2014 > Beta testing of chewable cannabis extract completed
Beta testing of chewable cannabis extract completed
Submitted By SK3 Group, Inc.
SK3 Group, Inc., dba Medical Greens, through its subsidiary Berkely Bio-Organic Research Laboratories, has completed beta-testing of the initial offering in its recently announced phyto-cannabinoid product line, T-Hydrocanª.T-Hydrocanª RMC 40 contains 40 mg. of refined mixed cannabinoids which have been extracted from cannabis flowers utilizing solvents approved for food contact, refined via numerous filtration and separation processes to remove as many of the non-cannabinoid elements as possible, and pressed into a chewable tablet.
Unlike Medical Greens' non-psychoactive Dharmanolª product line, T-Hydrocanª RMC 40 contains fully-activated (decarboxylated) THC, producing the classic effects of medical marijuana via an orally-consumed tablet.
"While we are most excited about the possibilities of the non-psychoactive cannabinoids, the great bulk of the research, as well as the majority of the scientific knowledge of the medicinal healing effects ascribed to cannabis medicine, come from research performed on psychoactive THC. Orally-consumed doses of various types and strengths of traditional cannabis extracts have shown substantial efficacy in treating pain, anxiety, insomnia, anorexia, as well as numerous other conditions. T-Hydrocan RMC 40 tablets have been designed to benefit those seeking relief from these, and many other conditions that have been successfully treated with medicinal cannabis," said David Hoye of Berkeley Bio-Organic Research Laboratory.
T-Hydrocanª RMC 40 tablets will now be packaged and made available to qualified California medical patients through the network of medicinal collectives serviced and managed by Medical Greens, as well as through the Pharmajanes.com ordering platform.
Full text of press release at: SKTO_3-12-2014_PAP_ETL.docx